These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 8839236)

  • 1. Detection of antibodies to human melanoma cells in vitiligo and alopecia areata by Western blot analysis.
    Hann SK; Koo SW; Kim JB; Park YK
    J Dermatol; 1996 Feb; 23(2):100-3. PubMed ID: 8839236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of antibodies to human melanoma cell in vitiligo by western blot analysis.
    Hann SK; Kim JB
    Yonsei Med J; 1995 Nov; 36(5):457-61. PubMed ID: 8546004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells.
    Cui J; Bystryn JC
    Arch Dermatol; 1995 Mar; 131(3):314-8. PubMed ID: 7887661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Western blot analysis of serum antibody reactivity with human melanoma cell antigens in alopecia areata and vitiligo.
    Galbraith GM; Miller D; Emerson DL
    Clin Immunol Immunopathol; 1988 Sep; 48(3):317-24. PubMed ID: 3042212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor antigens isolated from a patient with vitiligo and T-cell-infiltrated melanoma.
    Kiniwa Y; Fujita T; Akada M; Ito K; Shofuda T; Suzuki Y; Yamamoto A; Saida T; Kawakami Y
    Cancer Res; 2001 Nov; 61(21):7900-7. PubMed ID: 11691810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epitopes, avidity and IgG subclasses of tyrosine hydroxylase autoantibodies in vitiligo and alopecia areata patients.
    Rahoma SF; Sandhu HK; McDonagh AJ; Gawkrodger DJ; Weetman AP; Kemp EH
    Br J Dermatol; 2012 Jul; 167(1):17-28. PubMed ID: 22329856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo).
    Merimsky O; Shoenfeld Y; Baharav E; Zigelman R; Fishman P
    Hum Antibodies Hybridomas; 1996; 7(4):151-6. PubMed ID: 9140726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stress in patients with alopecia areata and vitiligo.
    Manolache L; Benea V
    J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):921-8. PubMed ID: 17659001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of antibodies to melanocytes in vitiligo by western immunoblotting.
    Hann SK; Shin HK; Park SH; Reynolds SR; Bystryn JC
    Yonsei Med J; 1996 Dec; 37(6):365-70. PubMed ID: 9048487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hair follicle structures targeted by antibodies in patients with alopecia areata.
    Tobin DJ; Hann SK; Song MS; Bystryn JC
    Arch Dermatol; 1997 Jan; 133(1):57-61. PubMed ID: 9006373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality?
    Ram M; Shoenfeld Y
    Ann N Y Acad Sci; 2007 Sep; 1110():410-25. PubMed ID: 17911456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
    Rosenberg SA; White DE
    J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):81-4. PubMed ID: 8859727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Humoral and cellular autoimmunity in genuine vitiligo studied by means of an antigen produced from melanoma cells].
    Höfs T
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(2):244-50. PubMed ID: 6179826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue-specific autoantibodies and autoimmune disorders in vitiligo and alopecia areata: a retrospective study.
    Korkij W; Soltani K; Simjee S; Marcincin PG; Chuang TY
    J Cutan Pathol; 1984 Dec; 11(6):522-30. PubMed ID: 6520261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimelanoma immunity in vitiligo and melanoma patients.
    Juranic ZD; Stanojevic-Bakic N; Zizak Z; Babovic N; Radovic-Kovacevic V; Stanojkovic T; Dzodic R
    Neoplasma; 2003; 50(4):305-9. PubMed ID: 12937846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Qualitative difference between the cytotoxic T lymphocyte responses to melanocyte antigens in melanoma and vitiligo.
    Palermo B; Garbelli S; Mantovani S; Scoccia E; Da Prada GA; Bernabei P; Avanzini MA; Brazzelli V; Borroni G; Giachino C
    Eur J Immunol; 2005 Nov; 35(11):3153-62. PubMed ID: 16224813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies to hair follicles in alopecia areata.
    Tobin DJ; Orentreich N; Fenton DA; Bystryn JC
    J Invest Dermatol; 1994 May; 102(5):721-4. PubMed ID: 8176253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The protective role of the HLA-DR locus in patients with various clinical types of alopecia areata.
    Broniarczyk-Dyła G; Prusińska-Bratoś M; Dubla-Berner M; Arkuszewska C; Borowiec M; Kowalski ML; Woszczek G
    Arch Immunol Ther Exp (Warsz); 2002; 50(5):333-6. PubMed ID: 12455867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of pigment cell antigens defined by vitiligo antibodies.
    Cui J; Harning R; Henn M; Bystryn JC
    J Invest Dermatol; 1992 Feb; 98(2):162-5. PubMed ID: 1370675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy.
    Okamoto T; Irie RF; Fujii S; Huang SK; Nizze AJ; Morton DL; Hoon DS
    J Invest Dermatol; 1998 Dec; 111(6):1034-9. PubMed ID: 9856813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.